Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells

The therapeutic landscape for chronic myeloid leukemia (CML) has improved significantly with the approval of tyrosine kinase inhibitors (TKIs) for therapeutic use. Most patients with optimal responses to TKIs can have a normal life expectancy. Treatment-free remission (TFR) after discontinuing TKI h...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yilin, Zou, Jing, Cheng, Fanjun, Li, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581243/
https://www.ncbi.nlm.nih.gov/pubmed/34778088
http://dx.doi.org/10.3389/fonc.2021.769730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581243/
https://www.ncbi.nlm.nih.gov/pubmed/34778088
http://dx.doi.org/10.3389/fonc.2021.769730

Ejemplares similares